Volume 2.40 | Oct 22

Immune Regulation News 2.40, October 22, 2010.
In this issue: Science News  |  Current Publications  |  Industry News  |  Policy News  |  Events Subscribe  |  Unsubscribe

TOP STORY

NIH Scientists Discover Secrets of Helper T Cells Involved in Autoimmunity  ShareThis
Scientists have redefined the roles of several cytokines involved in the generation of immune cells implicated in severe autoimmune diseases. The study in mice showed that development of Th17 immune cells can occur without the presence of transforming growth factor-beta, a mediator thought to be required for Th17 cell development. [Press release from the National Institutes of Health discussing online prepublication in Nature]

CellFrequenciesWallchart_645x110


SPECIAL FEATURE

Interested in recruiting talented individuals? Post your career opportunities in Immune Regulation News at no cost. Contact us at [email protected]


SCIENCE NEWS

Novel Regulatory Process for T Cells May Help Explain Immune System Diseases
A newly identified regulatory process affecting the biology of immune system T cells should give scientists new approaches to explore the causes of autoimmunity and immune deficiency diseases. [Press release from the Cincinnati Children’s Hospital Medical Center discussing online prepublication in the Proceedings of the National Academy of Sciences USA]

Elusive Protein May Lead the Fight Against Inflammatory Disease
A research team has identified a protein that may be a key therapy for many inflammatory diseases, including those affecting premature babies. [Press release from the Monash Institute of Medical Research discussing online prepublication in Nature Immunology]

Read the Review  
Stress-Free Isolation of Highly Purified Mouse CD4+ T Cells
with EasySep®
 
 
READ THE REVIEW STEMCELL Technologies Inc
 


CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal)

Generation of Pathogenic TH17 Cells in the Absence of TGF-Beta Signalling
Here, researchers show that TH17 differentiation can occur in the absence of TGF-beta signalling. [Nature]

IL-37 is a Fundamental Inhibitor of Innate Immunity
Expression of IL-37 in macrophages or epithelial cells almost completely suppressed production of pro-inflammatory cytokines, whereas the abundance of these cytokines increased with silencing of endogenous IL-37 in human blood cells. [Nat Immunol]

IL-35-Mediated Induction of a Potent Regulatory T Cell Population
Here, researchers show that treatment of naive human or mouse T cells with IL-35 induced a regulatory population, which researchers call ‘iTR35 cells’, that mediated suppression via IL-35 but not via the inhibitory cytokines IL-10 or transforming growth factor-beta. [Nat Immunol]

Intravital Imaging Reveals Distinct Dynamics for Natural Killer and CD8+ T Cells During Tumor Regression
Recognition of NKG2D ligands by natural killer (NK) cells plays an important role during antitumoral responses. To address how NKG2D engagement affects intratumoral NK cell dynamics, researchers performed intravital microscopy in a Rae-1beta-expressing solid tumor. [Immunity]

Histone Deacetylase Inhibitors Impair Innate Immune Responses to Toll-Like Receptor Agonists and to Infection
Here, researchers describe the effects of histone deacetylase inhibitors on microbial sensing by macrophages and dendritic cells in vitro and host defenses against infection in vivo. [Blood]

Bortezomib Suppresses Function and Survival of Plasmacytoid Dendritic Cells by Targeting Intracellular Trafficking of Toll-Like Receptors and Endoplasmic Reticulum Homeostasis
Here, researchers show that a proteasome inhibitor bortezomib suppresses survival and immunostimulatory function of human plasmacytoid dendritic cells by targeting two critical points, intracellular trafficking of nucleic acid-sensing Toll-like receptors and endoplasmic reticulum homeostasis. [Blood]

Coordination of IL-7 Receptor and T Cell Receptor Signaling By Cell-Division Cycle 42 in T Cell Homeostasis
Here, researchers demonstrate that T cell-specific deletion of cell-division cycle 42 (Cdc42) GTPase causes a profound loss of mature T cells. [Proc Natl Acad Sci USA]

T Cell Receptor-Driven Lymphomagenesis in Mice Derived from a Reprogrammed T Cell
The lymphomagenesis in mice derived from a reprogrammed T cell demonstrates the deleterious consequences of misregulation of the T cell receptor rearrangement and signaling pathways and illustrates one case of cellular reprogramming where the identity of the cell of origin has profound consequences. [Proc Natl Acad Sci USA]

The Adapters EAT-2A and -2B Are Positive Regulators of CD244- and CD84-Dependent NK Cell Functions in the C57BL/6 Mouse
To evaluate whether the genetic background or the presence of a selection marker in the mutant mice could influence the regulatory mode of these adapters, researchers generated EWS/FLI1-activated transcript (EAT)-2A-, EAT-2B-, and EAT-2A/B-deficient mice using C57BL/6 embryonic stem cells. [J Immunol]

On How Monospecific Memory-Like Autoregulatory CD8+ T Cells Can Blunt Diabetogenic Autoimmunity: A Computational Approach
Here, researchers examine the dynamics of memory autoregulatory CD8+ T cells specific for islet-specific glucose-6-phosphatase catalytic subunit-related protein(206-214), a prevalent beta cell autoantigen; their high-avidity counterparts (dominant effectors); and all other autoreactive non-islet-specific glucose-6-phosphatase catalytic subunit-related protein(206-214)-specific CD8+ T cell specificities (subdominant effectors) in response to peptide-major histocompatibility complex-coated nanoparticle therapy. [J Immunol]


INDUSTRY NEWS

Talecris Biotherapeutics Receives FDA Approval for Gamunex(R)-C
Talecris Biotherapeutics announced that the U.S. Food and Drug Administration (FDA) approved Gamunex(R)-C (Immune Globulin Injection [Human], 10% Caprylate/Chromatography Purified) for subcutaneous administration in the treatment of primary immunodeficiency. [Talecris Biotherapeutics, Inc. Press Release]

Idera Pharmaceuticals Presents Phase I Clinical Data for IMO-3100, Lead Candidate for the Treatment of Autoimmune Diseases, and Provides Program Update
Idera Pharmaceuticals, Inc. announced results from its single-dose, dose-escalation Phase I clinical trial evaluating the safety and mechanism of action of IMO-3100, its lead Toll-like Receptor (TLR) 7 and TLR9 antagonist drug candidate for the treatment of autoimmune and inflammatory diseases. [Idera Pharmaceuticals, Inc. Press Release]

MannKind Announces Initiation of Phase II Trial of Cancer Vaccine for Advanced Melanoma
MannKind Corporation announced the first patient has been dosed in a Phase II clinical trial of the novel, investigational cancer vaccine MKC1106-MT. [MannKind Corporation Press Release]


POLICY NEWS

European Medicines Agency Strengthens Rules on Conflicts of Interests of Its Scientific Experts
The European Medicines Agency has published new rules on how the Agency will be handling potential conflicts of interests of its scientific experts, following endorsement by its Management Board. [European Medicines Agency, European Union]

IQWiG: Law Must Prescribe Obligation to Publish All Clinical Trials
If the currently discussed draft on the “Law on the Reorganization of the Pharmaceutical Market” (AMNOG) is implemented, drug manufacturers will in future have to register their clinical trials at inception and publish results after completion. [Institute for Quality and Efficiency in Health Care (IQWiG), Germany]

Loss of UK Genetics Public Bodies Confirmed
The official announcement from the UK Government on the future of non-departmental public bodies has confirmed the rumored abolition of a total of 192 public bodies, with a further 118 to be merged. [Foundation for Genomics and Population Health, United Kingdom]

HHS to Let Secretary’s Genetics Committee Expire 
The Secretary’s Advisory Committee on Genetics, Health, and Society will disband next month, eight years after its founding. The committee had completed its original task, advising the Department of Health and Human Services (HHS) on a number of issues related to genomics. [Department of Health and Human Services, United States]

Screening Framework Guidance for Providers of Synthetic Double-Stranded DNA (FR Doc. 2010-25728) [Department of Health and Human Services, United States]

Proposed Collection; Comment Request; National Evaluation of the Clinical and Translational Science Awards (CTSA) Initiative (FR Doc. 2010-25589) [Department of Health and Human Services, United States]

Agency Information Collection Request. 30-Day Public Comment Request (FR Doc. 2010-25587) [Department of Health and Human Services, United States]

Partnerships To Advance the National Occupational Research Agenda (NORA) (FR Doc. 2010-25973) [Centers for Disease Control and Prevention, United States]

Office of the Director, National Institutes of Health; Notice of Meeting (FR Doc. 2010-26036) [National Institutes of Health, United States]

National Human Genome Research Institute; Notice of Closed Meeting (FR Doc. 2010-25634) [National Institutes of Health, United States]

Center for Scientific Review; Notice of Closed Meetings (FR Doc. 2010-25595) [National Institutes of Health, United States]

Center for Scientific Review; Notice of Closed Meetings (FR Doc. 2010-25597) [National Institutes of Health, United States]

Center for Scientific Review; Amended Notice of Meeting (FR Doc. 2010-25598) [National Institutes of Health, United States]

Center for Scientific Review; Amended Notice of Meeting (FR Doc. 2010-25601) [National Institutes of Health, United States]

Center for Scientific Review; Notice of Closed Meetings (FR Doc. 2010-26028) [National Institutes of Health, United States]

Center for Scientific Review; Notice of Closed Meetings (FR Doc. 2010-26033) [National Institutes of Health, United States]

National Cancer Institute; Notice of Closed Meeting (FR Doc. 2010-25636) [National Institutes of Health, United States]

National Cancer Institute; Notice of Closed Meeting (FR Doc. 2010-25640) [National Institutes of Health, United States]

National Cancer Institute; Notice of Meeting (FR Doc. 2010-26032) [National Institutes of Health, United States]

National Cancer Institute; Notice of Closed Meetings (FR Doc. 2010-26035) [National Institutes of Health, United States]

National Institute of General Medical Sciences; Notice of Closed Meeting (FR Doc. 2010-26037) [National Institutes of Health, United States]

National Institute of General Medical Sciences; Notice of Closed Meeting (FR Doc. 2010-26075) [National Institutes of Health, United States]


EVENTS (Listed by Date)

The 8th Asia Pacific Congress of Allergy, Asthma and Clinical Immunology
November 7-10, 2010
Singapore

GTCbio 8th Annual Vaccines: “All Things Considered” Conference
November 8-9, 2010
Washington, D.C., United States

2010 Annual Meeting of the American College of Allergy, Asthma & Immunology
November 11-16, 2010
Phoenix, United States

Understanding Dendritic Cells and Their Ability to Regulate Immune Responses
November 12, 2010
Hertfordshire, United Kingdom

39th Autumn Immunology Conference
November 19-22, 2010
Chicago, United States

American Association for Cancer Research (AACR): Tumor Immunology – Basic and Clinical Advances
November 30-December 3, 2010
Miami, United States

Cell Symposia: Influenza – Translating Basic Insights
December 2-4, 2010
Washington, D.C., United States

5th Annual Stem Cell Meeting on the Mesa
December 7, 2010
La Jolla, United States

The 50th Midwinter Conference of Immunologists at Asilomar
January 22-25, 2011
Pacific Grove, United States

Phacilitate 7th Annual Cell & Gene Therapy Forum 2011
January 24-26, 2011
Washington, D.C., United States

Phacilitate 9th Annual North American Vaccine Forum
January 24-26, 2011
Washington, D.C., United States

AACR-ACS Joint Meeting on Chemistry in Cancer Research: The Biological Chemistry of Inflammation as a Cause of Cancer
January 30-February 2, 2011
San Diego, United States

Keystone Symposia: Dendritic Cells and the Initiation of Adaptive Immunity
February 12-17, 2011
Santa Fe, United States

Keystone Symposia: Genetics, Immunology and Repair in Multiple Sclerosis
February 15-20, 2011
Taos, United States

BMT Tandem Meetings (ASBMT/CIBMTR)
February 17-21, 2011
Honolulu, Hawaii

18th Conference on Retroviruses and Opportunistic Infections (CROI 2011)
February 27-March 2, 2011
Boston, United States

The 6th International Conference on Oncolytic Viruses as Cancer Therapeutics
March 16-19, 2011
Las Vegas, United States

2011 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting
March 18-22, 2011
San Francisco, United States

Microbiota and Mucosal Immunology: The Interface in Health and Disease
April 14-16, 2011
San Francisco, United States

GTCbio 2nd International Conference on Cancer Immunotherapy & Immunomonitoring
May 2-5, 2011
Budapest, Hungary

American Society of Gene and Cell Therapy (ASGCT) 14th Annual Meeting
May 18-21, 2011
Seattle, United States

Gordon Research Conference: Viruses & Cells
May 29-June 3, 2011
Lucca (Barga), Italy

Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.


JOB OPPORTUNITIES

Clean Room Team Leader – Cellular Therapy (Cell Medica Limited)

Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Cell Therapy News at no cost.

Visit here to post your career opportunities.



Have we missed an important article or publication in Immune Regulation News? Click here to submit!




Comments or Suggestions? Email [email protected] with your feedback.


Learn more about Immune Regulation News: Archives  |  Events  |  Subscribe  |  Contact Us